A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22310%2F22%3A43922345" target="_blank" >RIV/60461373:22310/22:43922345 - isvavai.cz</a>
Result on the web
<a href="http://ttps://www.sciencedirect.com/science/article/pii/S0264410X21016765" target="_blank" >http://ttps://www.sciencedirect.com/science/article/pii/S0264410X21016765</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.vaccine.2021.12.068" target="_blank" >10.1016/j.vaccine.2021.12.068</a>
Alternative languages
Result language
angličtina
Original language name
A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae
Original language description
Streptococcus pneumoniae (S. pneumoniae) infections are the leading cause of child mortality globally. Current vaccines fail to induce a protective immune response towards a conserved part of the pathogen, resulting in new serotypes causing disease. Therefore, new vaccine strategies are urgently needed. Described is a two-pronged approach combining S. pneumoniae proteins, pneumolysin (Ply) and pneumococcal surface protein A (PspA), with a precisely defined synthetic oligosaccharide, whereby the carrier protein acts as a serotype-independent antigen to provide additional protection. Proof of concept in mice and swine models revealed that the conjugates inhibited colonization of the nasopharynx, decreased the bacterial load and reduced disease severity in the bacteria challenge model. Immunization of piglets provided the first evidence for the immunogenicity and protective potential of synthetic glycoconjugate vaccine in a large animal model. A combination of synthetic oligosaccharides with proteins from the target pathogen opens the path to create broadly cross-protective (“universal”) pneumococcal vaccines.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Vaccine
ISSN
0264-410X
e-ISSN
0264-410X
Volume of the periodical
40
Issue of the periodical within the volume
7
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
9
Pages from-to
1038-1046
UT code for WoS article
000750903800011
EID of the result in the Scopus database
2-s2.0-85122955438